Ocugen Inc
F:2H51
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Ocugen Inc
F:2H51
|
US |
|
H
|
Hacksaw AB
STO:HACK
|
SE |
|
Drax Group PLC
LSE:DRX
|
UK |
|
I
|
ING Bank Slaski SA
WSE:ING
|
PL |
|
Turners Automotive Group Ltd
NZX:TRA
|
NZ |
|
K
|
Korea Asset Investment Securities Co Ltd
KOSDAQ:190650
|
KR |
|
O
|
Origin Energy Ltd
XMUN:ORL
|
AU |
Intrinsic Value
Is 2H51 undervalued or overvalued?
See the intrinsic value estimate for 
Ocugen Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
2H51 looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with 2H51’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Ocugen Does
Ocugen is a biotechnology company that focuses on treatments for eye diseases, especially inherited retinal disorders that can lead to vision loss. Its work centers on developing gene therapies and other biologic medicines that aim to treat the underlying cause of disease rather than just the symptoms.
- Headquarters
- United States of America US
- Employees
- 116
- IPO date
- Dec 3, 2014
Revenue & Expenses Breakdown
Ocugen Inc
Earnings Waterfall
Ocugen Inc
The intrinsic value for Ocugen Inc (2H51) under the Base Case is hidden EUR.
Compared with the current market price of 0.725 EUR, the stock appears hidden.